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Abstract
BACKGROUND: Cardiac resynchronisation therapy (CRT) is increasingly used in children in a variety
of anatomical and pathophysiological conditions, but published data are scarce. OBJECTIVE: To record
current practice and results of CRT in paediatric and congenital heart disease. DESIGN: Retrospective
multicentre European survey. SETTING: Paediatric cardiology and cardiac surgery centres. PATIENTS:
One hundred and nine patients aged 0.24-73.8 (median 16.9) years with structural congenital heart
disease (n = 87), congenital atrioventricular block (n = 12) and dilated cardiomyopathy (n = 10) with
systemic left (n = 69), right (n = 36) or single (n = 4) ventricular dysfunction and ventricular
dyssynchrony during sinus rhythm (n = 25) or associated with pacing (n = 84). INTERVENTIONS:
CRT for a median period of 7.5 months (concurrent cardiac surgery in 16/109). MAIN OUTCOME
MEASURES: Functional improvement and echocardiographic change in systemic ventricular function.
RESULTS: The z score of the systemic ventricular end-diastolic dimension decreased by median 1.1
(p<0.001). Ejection fraction (EF) or fractional area of change increased by a mean (SD) of 11.5 (14.3)%
(p<0.001) and New York Heart Association (NYHA) class improved by median 1.0 grade (p<0.001).
Non-response to CRT (18.5%) was multivariably predicted by the presence of primary dilated
cardiomyopathy (p = 0.002) and poor NYHA class (p = 0.003). Presence of a systemic left ventricle was
the strongest multivariable predictor of improvement in EF/fractional area of change (p<0.001). Results
were independent of the number of patients treated in each contributing centre. CONCLUSION: Heart
failure associated with ventricular pacing is the largest indication for CRT in paediatric and congenital
heart disease. CRT efficacy varies widely with the underlying anatomical and pathophysiological
substrate.
doi: 10.1136/hrt.2008.160465
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ABSTRACT
Background: Cardiac resynchronisation therapy (CRT) is
increasingly used in children in a variety of anatomical and
pathophysiological conditions, but published data are
scarce.
Objective: To record current practice and results of CRT
in paediatric and congenital heart disease.
Design: Retrospective multicentre European survey.
Setting: Paediatric cardiology and cardiac surgery
centres.
Patients: One hundred and nine patients aged 0.24–73.8
(median 16.9) years with structural congenital heart
disease (n = 87), congenital atrioventricular block
(n = 12) and dilated cardiomyopathy (n = 10) with
systemic left (n = 69), right (n = 36) or single (n = 4)
ventricular dysfunction and ventricular dyssynchrony
during sinus rhythm (n = 25) or associated with pacing
(n = 84).
Interventions: CRT for a median period of 7.5 months
(concurrent cardiac surgery in 16/109).
Main outcome measures: Functional improvement and
echocardiographic change in systemic ventricular func-
tion.
Results: The z score of the systemic ventricular end-
diastolic dimension decreased by median 1.1 (p,0.001).
Ejection fraction (EF) or fractional area of change
increased by a mean (SD) of 11.5 (14.3)% (p,0.001) and
New York Heart Association (NYHA) class improved by
median 1.0 grade (p,0.001). Non-response to CRT
(18.5%) was multivariably predicted by the presence of
primary dilated cardiomyopathy (p = 0.002) and poor
NYHA class (p = 0.003). Presence of a systemic left
ventricle was the strongest multivariable predictor of
improvement in EF/fractional area of change (p,0.001).
Results were independent of the number of patients
treated in each contributing centre.
Conclusion: Heart failure associated with ventricular
pacing is the largest indication for CRT in paediatric and
congenital heart disease. CRT efficacy varies widely with the
underlying anatomical and pathophysiological substrate.
Cardiac resynchronisation therapy (CRT) has
become a standard treatment for adults with
idiopathic or ischaemic cardiomyopathy and sys-
temic ventricular dyssynchrony. Improvement in
ventricular function, functional status and
decreased mortality has been shown in recent large
randomised trials.1 2 CRT has also been applied to
the paediatric and congenital heart disease popula-
tion. So far only a few case reports,3–5 small
uncontrolled studies6–9 and one retrospective multi-
centre survey10 have reported benefit from CRT in
this complex population. The aim of this multi-
centre European experience was to record the
current practice of this evolving therapy, indica-
tions and predictors of benefit or failure in various
anatomical and pathophysiological situations.
METHODS
Data collection
Data from patients with structural congenital
heart disease and congenital complete atrioventri-
cular block regardless of age and from patients
with dilated cardiomyopathy under the age of 21
years subjected to CRT up to the deadline of data
collection were gathered retrospectively. Data
collected consisted of demographics, underlying
heart disease and its surgical treatment, morphol-
ogy of the systemic ventricle, preceding ventricular
pacing, New York Heart Association (NYHA) class
and the method used to identify electromechanical
dyssynchrony. Details of CRT system implanta-
tion were documented. Heart transplant listing,
complications of CRT as well as death were noted.
Non-responders were defined as those not respond-
ing clinically (decrease in NYHA class) and having
no improvement in systemic ventricular function.
Given the retrospective study design and the wide
range of ages, functional assessment using the
6 min walk test or quantitative cardiopulmonary
testing was not required.
Echocardiographic data
End-diastolic and end-systolic dimensions of the
systemic ventricle were measured at the point of
peak diastolic systemic ventricular free wall outward
motion and peak systolic inward motion, respec-
tively, and expressed as a z score indexed to a normal
systemic left ventricle (LV).11 Systemic ventricular
shortening fraction was calculated according to the
following formula: ((end-diastolic dimension – end-
systolic dimension)/end-diastolic dimension)6100.
In patients with a systemic LV the ejection fraction
(EF) was measured by either the biplane Simpson
method or the Teichholz method. Care was taken to
use the same measurement method before CRT and
Heart failure and cardiomyopathy
Heart 2009;95:1165–1171. doi:10.1136/hrt.2008.160465 1165
 group.bmj.com on January 26, 2010 - Published by heart.bmj.comDownloaded from 
at the last follow-up in each individual patient. For a systemic
right ventricle (RV) or functionally single ventricle, the fractional
area of change was measured from the apical four-chamber view.
The grade of systemic atrioventricular valve was assessed using
usual semiquantitative grading as none = 0, mild = 1, moder-
ate = 2 and severe = 3.12 No details of mechanical dyssynchrony
evaluation other than the method used were obtained.
Statistical analysis
Values are expressed as either median (range) or mean (SD)
depending on the distribution pattern of the data. Differences in
continuous variables among groups of patients were evaluated
by one-way analysis of variance, two-tailed t test or Mann–
Whitney rank sum test, as appropriate. Paired comparisons were
performed by paired t test. Predictors of improvement in systolic
function and non-response to CRT were evaluated by univariate
tests and were entered into a multivariable analysis (backward
stepwise regression) if showing significant univariate correla-
tion. The following independent variables were used: age at CRT,
type of heart disease, systemic ventricular morphology, preceding
ventricular pacing, initial QRS duration, QRS shortening by CRT,
initial NYHA class, z score of the systemic ventricular end-
diastolic diameter, shortening fraction, EF or fractional area of
change and grade of systemic atrioventricular valve regurgitation.
For the comparison between large- and small-volume centres the
institutions were divided into two groups with either.10 or (10
reported patients (fig 1). p Values ,0.05 were considered
significant. Calculations were performed using SigmaStat 3.1
and SigmaPlot 9.1 for Windows (SPSS, Chicago, Illinois, USA).
RESULTS
Demographics
The study group comprised 109 patients from 17 European
paediatric cardiology and cardiac surgery centres (fig 1) with a
median age 16.9 years (range 2.9 months–73.8 years) at
initiation of CRT, and subsequent follow-up of a median of
7.5 months. The systemic ventricle was morphologically left in
69 patients, right in 36 and four patients had a functionally
single ventricle. Eighty-two patients (75.2%) had a history of
preceding major cardiac surgery (tables 1 and 2). Twenty-three
patients from two centres (No 2 (Kardiocentrum and
Cardiovascular Research Centre, Czech Republic) and 6
(Evelina Children’s Hospital, Guy’s and St Thomas’ Trust,
London)) have been included in the previously published study
by Dubin et al.10 Follow-up for these patients is longer in the
current report.
Electrical dyssynchrony
Twenty-five patients (23%) had ventricular dyssynchrony
during intrinsic conduction. Ten patients (9%) had left bundle
branch block with a systemic LV and five patients had right
bundle branch block with a systemic right or functionally single
ventricle. The remaining 10/25 patients had non-specific QRS
prolongation. The majority of study patients (84/109, 77%) had
dyssynchrony associated with single-site ventricular pacing for a
median of 5.6 years (range 3 days–25.1 years) before the upgrade
to CRT. Of those, all but six patients were paced from the
subpulmonary chamber.
Mechanical dyssynchrony
The majority of patients (105/109, 96%) underwent evaluation of
mechanical dyssynchrony by either conventional echocardiography
Figure 1 Number of patients contributed by each centre (centres are
numbered according to the number used in the author affiliations).
Table 1 Patient data and CRT effects according to diagnostic group
Patient data
All
(n = 109)
CHD (CRT only)
(n = 71)
CHD (CRT +
concurrent cardiac
surgery)
(n = 16)
Congenital AV
block
(n = 12)
DCMP
(n = 10) p Value*
Age at CRT (years), median 16.9 25.5 13.9 3.6 12.7 ,0.001
Follow-up on CRT (months), median 7.5 8.8 4.0 9.5 2.3 0.099
Initial QRS (ms), median 160 160 160 155 144 0.082
Initial SVEDD (z score), median 3.3 2.5 2.6 3.7 5.5 0.131
Initial EF/FAC (%), median 27.0 27.5 24.5 24.5 22.0 0.602
Initial SAVV regurgitation (grade), median 1 1 0 1 2 0.589
Initial NYHA class (median) 2.5 2.5 2.0 2.5 4.0 0.058
Change in QRS (ms), median 2401 2401 2461 2401 215 0.268
Change in SVEDD (z score), median 21.11 21.21 20.8 22.2" 20.4 0.582
Change in EF/FAC (%), mean (SD) +11.5 (14.3)1 +9.9 (13.8)1 +12.3 (17.1)" +23.5 (12.2)" +10.8 (11.9)% 0.358
Change in SAVV regurgitation (grade), median 211 0 0 21" 0 0.556
Change in NYHA class (median) 21.01 21.01 21.0{ 21.0{ 0.0 0.028
Non-responders 15/94 7/60 0/13 2/12 6/9 ,0.001
*Significance levels across diagnostic categories; significance levels inside diagnostic categories pre-CRT vs post-CRT: {p,0.01; {p,0.005; 1p,0.001; "p,0.05.
AV, atrioventricular; CHD, congenital heart disease; CRT, cardiac resynchronisation therapy; DCMP, dilated cardiomyopathy; EF, ejection fraction; FAC, fractional area of change; NS,
non-significant; NYHA, New York Heart Association; SAVV, systemic atrioventricular valve; SVEDD, systemic ventricular end-diastolic dimension.
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(92 patients) and/or by tissue Doppler imaging (67 patients)
without a prespecified protocol.
CRT implantation
A transvenous approach was used in 45 (41%) patients,
thoracotomy in 36 (33%) patients and a combined approach
in 28 (26%) patients. Patients in the transvenous group were
significantly older: median 33.5 (7.1–73.8) vs 8.4 (0.2–67.5) years
(p,0.001). Two ventricular leads were used in 105 patients.
Two patients with a systemic LV and RV, respectively, had
resynchronisation by a single ventricular lead placed trans-
venously or by thoracotomy at the site of ventricular conduc-
tion delay. Finally, one patient with transposition of great
arteries after the atrial switch procedure and another patient
with a functionally single ventricle received three ventricular
leads in an attempt to better resynchronise a severely dilated
ventricle. Additional concurrent cardiac surgery was performed
in 16 patients (15%). CRT systems with defibrillating capability
were used in 20 patients (18%).
QRS change
QRS duration decreased from a median of 160 ms before CRT
implantation to 130 ms at last follow-up (p,0.001). Initial QRS
duration was significantly longer in patients paced before CRT
(mean (SD) 169 (28) ms) than in non-paced patients (mean 141
(30) ms, p,0.001). QRS shortening was also more pronounced
(median 240 vs 210 ms, p = 0.001) in the previously paced
group.
Reverse ventricular remodelling
Sufficient echocardiographic data to allow analysis was avail-
able in 89/109 patients. Table 1 summarises the impact of CRT
on the total population and the four different diagnostic groups,
with a significantly higher proportion of non-responders in the
dilated cardiomyopathy group. For all further analysis of change
in systemic ventricular size and function after CRT, patients
with concurrent cardiac surgical procedures were excluded.
After doing so the calculated overall increase in systemic
ventricular EF/fractional area of change and decrease in the z
score of the systemic ventricular end-diastolic dimension still
remained highly significant with +11.2 (13.7)% and median
21.3, respectively (p,0.001 for both).
Table 3 summarises the differences between patients with
systemic LV and RV. Initial systemic ventricular end-diastolic
dimension and its decrease after CRT were significantly
greater in patients with systemic LV. Patients with a systemic
LV who were upgraded to CRT from previous ventricular
pacing had a better response than the rest of the population
(mean increase in EF/fractional area of change of +14.0 (16.5)
vs 7.7 (10.9)%, p = 0.101, median decrease in the z score of
systemic ventricular end-diastolic dimension of 22.1 vs 20.8,
p = 0.036 and decrease in median NYHA class from 3.0 to 1.0
as compared with no change in median values, p = 0.030).
Approach to ventricular lead placement (transvenous vs
thoracotomy/combined) as well as patient volume (large vs
small volume centres) had no significant influence on
improvement of EF/fractional area of change (+13.8 (13.5)%
vs 7.6 (13.6)% and +9.1 (15.3)% vs 14.8 (12.4)%, respectively, p
value NS for both). Predictors of increase in EF/fractional area
of change could be evaluated in 31/109 patients with available
data and follow-up .3 months identifying the presence of a
systemic LV (p,0.001) and higher initial grade of systemic AV
valve regurgitation (p = 0.002) as the only significant factors
in a multivariable analysis.
Table 2 Structural cardiac diagnoses
Systemic LV (n = 69) Systemic RV (n = 36) Functionally single ventricle (n = 4)
Diagnosis n Diagnosis n Diagnosis n
TOF 11 cCTGA 20 SV 2
VSD 10 d-TGA 12 HLHS 1
d-TGA 4 DORV 4 Unbalanced AVSD 1
AS 3
ASD 4
AVSD 3
COA 2
PA-VSD 2
Shone complex 2
Other 6
Normal heart 22
AS, aortic stenosis; ASD, atrial septal defect; AVSD, atrioventricular septal defect; cCTGA, congenitally corrected transposition of
great arteries; COA, coarctation of aorta; DORV, double outlet right ventricle; d-TGA, d-transposition of great arteries; HLHS,
hypoplastic left heart syndrome; LV, left ventricle; PA-VSD, pulmonary atresia with ventricular septal defect; RV, right ventricle; SV,
single ventricle; TOF, tetralogy of Fallot.
Table 3 Patients’ data and CRT effects according to systemic
ventricular anatomy (patients with CRT and concurrent cardiac surgical
procedure excluded)
Patients’ data
Systemic LV
(n = 62)
Systemic RV
(n = 27) p Value*
Age at CRT (years), median 13.3 28.8 0.002
Follow-up on CRT (months), median 8.6 7.3 0.965
Initial QRS (ms), median 160 160 0.722
Initial SVEDD (z score), median 4.7 2.1 0.002
Initial EF/FAC (%), mean (SD) 30.6 (15.8) 28.8 (10.0) 0.723
Initial SAVV regurgitation (grade)
(median)
1 2 0.025
Initial NYHA class (median) 3.0 2.0 0.215
Change in QRS (ms), median 2401 2211 0.877
Change in SVEDD (z score), median 22.11 20.5 0.039
Change in EF/FAC (%), mean (SD) +13.3 (14.7)1 +7.2 (9.9)" 0.195
Change in SAVV regurgitation (grade),
median
211 21" 0.600
Change in NYHA class (median) 21.01 21.0{ 0.380
Non-responders 11/54 3/22 0.745
*Significance levels across diagnostic categories; significance levels inside diagnostic
categories pre- vs post-CRT: {p,0.005; 1p,0.001; "p,0.05.
CRT, cardiac resynchronisation therapy; EF, ejection fraction; FAC, fractional area of
change; LV, left ventricle; NS, non-significant; NYHA, New York Heart Association; RV,
right ventricle; SAVV, systemic atrioventricular valve; SVEDD, systemic ventricular
end-diastolic dimension.
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Systemic atrioventricular valve regurgitation
Patients with concurrent cardiac surgical procedures were
excluded from this analysis. Systemic mitral valve regurgitation
decreased from a median grade 1 to 0 after CRT (p,0.001) and
systemic tricuspid valve insufficiency from a median grade 2 to
1 (p = 0.037). Both initial and latest follow-up systemic
atrioventricular valve regurgitation grades were significantly
higher in patients with systemic RV than in those with
systemic LV (p = 0.025 and 0.005, respectively, table 3). The
decrease in systemic AV valve regurgitation was significantly
correlated with the increase in EF/fractional area of change
(R = 0.536, p,0.001).
Functional improvement
After excluding patients with concurrent cardiac surgical
procedures the overall NYHA class improved by a median of
1.0 grade (p,0.001). Table 1 gives data for specific patients. No
change in NYHA class could be seen in patients with dilated
cardiomyopathy. There was a positive correlation between
initial NYHA class and systemic ventricular end-diastolic
diameter (R = 0.554, p,0.001) but no correlation with short-
ening fraction or EF/fractional area of change.
Functionally single ventricle
Table 4 summarises the data for patients with a functionally
single ventricle. Three of the four patients improved after CRT.
Patients who underwent concurrent cardiac surgical procedures
Sixteen of the 109 patients (15%) had major cardiac surgery
along with CRT implementation, most commonly systemic
atrioventricular valve replacement or repair (7/16) in the
presence of systemic left (n = 3) or right ventricle (n = 4) or
pulmonary artery banding after previous atrial switch for
transposition of great arteries (n = 2). In general, these patients
had significant improvement in NYHA class (median 21.0
grade, p = 0.008) and EF/fractional area of change (+12.3
(17.1)%, p = 0.031) similar to the rest of the population
(table 1). None of these patients died or was judged a non-
responder.
CRT complications and discontinuation
Acute complications were noted in 10 patients (9.2%): pocket
haematoma (four patients), CRT lead dislodgement (two
patients, both were transvenous implants under the age of 15
years) and pneumothorax, ventricular fibrillation, fever or rise in
pacing threshold during anaesthesia leading to resuscitation
(one patient each). CRT had to be discontinued during follow-
up in nine patients (8.3%) because of lead failure in six,
worsening of heart failure in two and infection of the pacing
system in one patient. There was no significant difference in
acute complications and CRT discontinuation between patients
with transvenous and thoracotomy/mixed lead systems (4.7 vs
15.6% and 10.9 vs 4.4%, respectively) and between large and
small volume centres (9.8 vs 8.6% and 11.8 vs 5.2%,
respectively); p value NS for all.
Non-responders
Fifteen of 81 patients with available data and without
concurrent cardiac surgery (18.5%) were identified as non-
responders (table 5). Risk factors for non-response were
evaluated by univariate and multivariable analysis with the
only independent multivariable predictors being primary dilated
cardiomyopathy and initial poor NYHA class (table 6). Of the
six non-responders with primary dilated cardiomyopathy one
had a polyglucosan storage defect and two of the remaining five
with no apparent aetiology had baseline QRS duration
,100 ms, indicating absence of electrical dyssynchrony. These
two patients showed an increase in QRS duration after CRT.
Although CRT indication was based on echocardiographic
evaluation of mechanical dyssynchrony the interpretation
may have been wrong and improvement was not achieved.
There was no difference in the proportion of thoracotomy or
mixed lead systems between the responder and non-responder
group (33/66 vs 8/15 patients). Also there was no patient
volume-dependent effect (14.3% of non-responders in the large
volume vs 20.8% in the small volume centres, p = 0.560).
It is notable that the non-responders included four patients
(Nos 27, 28, 62 and 85, table 5) with the otherwise favourable
combination of a systemic LV and pacing-associated dyssyn-
chrony. These four patients had severely dilated LVs (z score of
the systemic ventricular end-diastolic diameter: +3.3 to +10.3)
and a high NYHA class. Patient No 27 underwent a Rastelli
procedure with subsequent mitral valve replacement and the
myocardial dysfunction may have been a consequence of
multiple operations. Patient No 28 had isolated congenital
complete atrioventricular block and no apparent reason for the
lack of response.
Patient No 62 died of malignant ventricular tachycardia
2 months after upgrade to biventricular pacing. Finally, patient
No 85 with end-stage heart failure died just 2 days after upgrade
to CRT owing to unstable haemodynamics.
Negative treatment outcomes
A total of 22 patients had negative outcomes owing to non-
response followed eventually by heart failure-related death or
heart transplantation (n = 15, table 5) or owing to discontinua-
tion of CRT for technical reasons or infection (n = 7).
Heart transplantation
Four of the 10 patients originally listed for heart transplantation
were removed from the transplant list because of improvement
in cardiac function after CRT. No significant predictors of
improvement could be found in this small group.
Table 4 Patients with functionally single ventricle
Patient
No
Age
(years)
Length of FUP
on CRT
(months)
Type of
surgical
repair Diagnosis
Previous
ventricular
pacing
No of
ventricular
leads
NYHA class
before CRT
NYHA class
after CRT Outcome
57 9.5 3.5 TCPC SV-LV Yes 2 3.0 3.0 Non-responder
59 3.7 0.5 TCPC HLHS No 3 3.0 2.0 Improved
70 11.0 7.9 BCPA Unbalanced AVSD Yes 2 2.0 1.0 Improved
79 30.3 19.9 TCPC SV Yes 2 2.5 2.0 Improved
AVSD, atrioventricular septal defect; BCPA, bi-directional cavopulmonary anastomosis; CRT, cardiac resynchronisation therapy; FUP, follow-up; HLHS, hypoplastic left heart
syndrome; NYHA, New York Heart Association; SV, unspecified single ventricle; SV-LV, morphologically left single ventricle; TCPC, total cavopulmonary connection.
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Death
During follow-up seven patients died (table 5). These patients
were similar to the non-responders characterised by a higher
NYHA class (median 4.0 as compared with 2.0 in the
survivors, p,0.001). Four of the patients died because of
end-stage heart failure. Two of the seven died of ventricular
arrhythmia.
DISCUSSION
CRT is a standard treatment option for adults with left
ventricular failure associated with mechanical dyssynchrony.
The benefits of CRT in paediatric patients and patients with
congenital heart disease have previously only been documented
in one large study including 103 patients.10 This retrospective
multicentre survey is the first analysis of CRT effects in
paediatric patients and patients with congenital heart disease
based on European data. As compared with the study by Dubin
et al10 our paper defines for the first time risk factors for non-
response or lack of improvement in systolic function and
presents additional important information about the use of
CRT in specific patient groups.
Patient population
This study reports patients with different pathophysiology of
systemic ventricular desynchronisation when compared with
adult idiopathic and ischaemic cardiomyopathy. The proportion
of patients with the typical combination of systemic LV and left
bundle branch block was low (9%). Furthermore, a majority had
ventricular desynchronisation associated with pacing (77%).
This figure exceeds the previously published 45% by Dubin et
al10 and suggests that alternative pacing strategies should be
considered in this patient population. Such finding is consistent
with the published adult and paediatric data on the adverse
effects of right ventricular pacing on LV synchrony,13 histol-
ogy,14 function7 8 15 16 and on morbidity and mortality due to
heart failure.17–19
Systemic ventricular morphology
A systemic LV was predictive of improvement in systolic
function and showed more extensive reverse remodelling,
whereas systemic right ventricular patients did worse. Both
pre- and post-CRT systemic atrioventricular valve regurgitation
was higher in subjects with systemic RV. This may be one of
the reasons for the less successful reverse remodelling in this
group. Patients with a systemic RV may mostly have structural
tricuspid valve regurgitation potentially less improvable by
resynchronisation than functional mitral regurgitation in
systemic LV.20 This is underscored by the fact that overall
improvement in systolic function did significantly correlate
with the decrease in systemic AV valve regurgitation. Thus the
combination of CRT with surgery aimed at decreasing tricuspid
valve regurgitation may be a valuable strategy as reflected by
our subgroup with concurrent cardiac surgical procedures, and
described elsewhere.7 Other reasons for the smaller benefit of
CRT in a systemic RV may lie in the different right ventricular
architecture and decreased myocardial perfusion reserve as
described in patients after atrial switch repair.21 22 Dubin et al10
reported similar improvement of EF in patients with a systemic
RV as in the whole CRT population, but did not analyse the
change in systemic ventricular size or systemic atrioventricular
valve regurgitation or compare these patients specifically with
the systemic LV cohort.Ta
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Ventricular dyssynchrony associated with pacing
Correction of electrical dyssynchrony by CRT was highly
successful in this patient subgroup, as shown by the significant
decrease in QRS duration in this and a previous study.10 Patients
with a systemic LV upgraded to CRT demonstrated major
clinical improvement and reverse LV remodelling. Dubin et al10
could not find a difference in EF improvement between patients
upgraded to CRT from single-site pacing and those with
primary CRT. In their study, however, patients were not
separated according to systemic ventricular morphology. As
seen in our non-responder group some paced patients with a
severely dilated LV may not benefit from an upgrade to CRT.
CRT might potentially have prevented irreversible LV damage if
applied earlier in the course of the disease. Recently, improve-
ment of LV function has been described after a simple change in
pacing site from the right ventricular epicardium to the LV
apex.23 It remains to be seen whether such a strategy may
constitute an alternative to upgrading to biventricular pacing.
Non-responders
A total of 15 non-responders (18.5% of patients with available
data and no concurrent cardiac surgery) were defined by the
participating investigators. This compares favourably with an
around one-third non-response rate in most adult CRT series
and is slightly higher than the previously published 10.7% in a
similar population.10
Two independent predictors of non-response were identified.
Patients with idiopathic dilated cardiomyopathy responded
poorly and less well than reported in the adult CRT population,
where resynchronisation was more successful in this setting
than with ischaemic aetiology. Several factors may have been
responsible including different aetiology of dilated cardiomyo-
pathy in the young (metabolic disease was present in one of the
non-responders) and potential absence of mechanical dyssyn-
chrony in another two, whose baseline QRS duration was short
and increased after CRT. The limited follow-up in this group
was rather a consequence than a reason for lack of response.
Table 5 shows that four of the six non-responders in the group
with dilated cardiomyopathy either died or received a transplant
shortly after CRT implementation. Worsening of haemody-
namics before a later positive effect would be quite unusual as
contraction efficacy improves immediately after CRT. Thus
CRT could not reverse the malignant course of the disease.
The other risk factor for non-response was poor initial NYHA
class. Whether this finding would argue in favour of offering
CRT at an earlier stage to prevent irreversible ventricular
deterioration is unclear from the present data. Whereas in the
report by Dubin et al10 the only difference between responders
and non-responders was the higher initial systemic EF in the
latter (‘‘too well to benefit’’ as speculated by the authors
themselves) and their analysis did not include type of heart
disease as an independent variable, our study was able to define
risk factors for non-response. In contrast to the cited report our
definition of non-responders required, besides the absence of an
increase in EF, lack of improvement in functional NYHA class.
Thus criteria used for identification of non-responders were
stronger and this may itself account for some differences in the
analysis.
Influence of patient volume
Interestingly, this study showed that CRT could be equally safe
and effective independently of the patient volume treated in
each contributing centre. All the participating institutions were,
however, tertiary centres combining an extensive cardiological
and surgical experience in treating congenital heart disease.
Thus, institutional background rather than the actual volume of
patients treated is probably more important to achieve
satisfactory results.
Limitations
The limitations of this study are its retrospective design, lack of
predefined indication criteria for CRT implantation, relatively
soft criteria for identification of CRT response (functional and/
or echocardiographic improvement), incomplete clinical and
echocardiographic datasets, methodological difficulties in the
evaluation of a systemic right ventricle and lack of other
functional assessment than the NYHA classification. The
systemic ventricular shortening fraction used for quantification
of systolic function may be inaccurate in the presence of
ventricular dyssynchrony. Its use was, however, limited to
evaluating changes due to CRT in selected individual patients in
whom EF or fractional area of change were not available. The
Table 6 Predictors of non-response to cardiac resynchronisation therapy (patients with CRT and concurrent
cardiac surgical procedure excluded)
Predictors
Responders
(n = 66)
Non-responders
(n = 15)
p Value
Univariate Multivariable
Congenital heart disease (%) 80.3 46.7 0.018 NS
Congenital complete AV block (%) 15.2 13.3 1.000 Not tested
Dilated cardiomyopathy (%) 4.5 40 ,0.001 0.002
Initial NYHA class (median) 2.0 3.0 ,0.001 0.003
Age at CRT (years), median 18.1 11.2 0.447 Not tested
Systemic right ventricle (%) 28.8 20.0 0.749 Not tested
Pacing before CRT (%) 81.8 60.0 0.087 Not tested
Initial SVEDD (z score), mean (SD) +3.5 (2.7) +6.3 (3.4) 0.003 NS
Initial SF (%), mean (SD) 17.3 (9.9) 12.9 (4.2) 0.148 Not tested
Initial EF/FAC (%), mean (SD) 31.6 (14.5) 22.5 (10.2) 0.101 Not tested
Initial SAVV regurgitation (grade), median 1 2 0.682 Not tested
Initial QRS duration (ms), median 160 150 0.301 Not tested
QRS shortening by CRT (ms), median 240 230 0.357 Not tested
Thoracotomy or mixed lead system (%) 50.0 53.3 1.000 Not tested
AV, atrioventricular; CRT, cardiac resynchronisation therapy; EF, ejection fraction; FAC, fractional area of change; NYHA, New York
Heart Association; SAVV, systemic atrioventricular valve; SF, shortening fraction; SVEDD, systemic ventricular end-diastolic
dimension.
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shortening fraction was not used for any analysis of overall
CRT efficacy. Further, accuracy of NYHA classification is
questionable in the congenital atrioventricular block group
owing to the median age of 3.6 years. Given the age of the
remaining patients, the small size of the congenital atrioven-
tricular block group and the limitation of the alternative Ross
heart failure score (applicable only to infants), the authors
nevertheless found that NYHA was useful and practical for
describing functional CRT efficacy in this retrospective setting.
Patients with primary dilated cardiomyopathy seem to be a
mixed population in this study making general conclusions
about CRT efficacy difficult. And, finally, this study was not
primarily focused on use of CRT in heart transplant candidates
and although some patients could be delisted after CRT, others
were transplanted because of non-response. Thus the utility of
CRT in this patient group cannot be clearly assessed from our
data. Despite these limitations and a wide variety of heart
disease included, the study group was large enough to allow for
meaningful and significant conclusions.
CONCLUSION
Overall, CRT in this population was at least as effective as in
adults with heart failure. The response was, however, dependent
on the structural and pathophysiological substrate being most
favourable after upgrades from single site to biventricular pacing
in patients with a systemic LV and generally less favourable in
patients with a systemic RV and in children with primary dilated
cardiomyopathy, where proper patient selection might improve
the results. NYHA class was poorly correlated with systemic
ventricular function and it is questionable whether it is a major
criterion for CRT indication in congenital heart disease.
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